Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) EPS (Weighted Average and Diluted) (2019 - 2021)

Historic EPS (Weighted Average and Diluted) for Pharming (PHAR) over the last 3 years, with Q1 2021 value amounting to -$11120.8.

  • Pharming's EPS (Weighted Average and Diluted) changed N/A to -$11120.8 in Q1 2021 from the same period last year, while for Mar 2021 it was -$9.9 million, marking a year-over-year change of. This contributed to the annual value of -$0.02 for FY2024, which is 1250.0% down from last year.
  • According to the latest figures from Q1 2021, Pharming's EPS (Weighted Average and Diluted) is -$11120.8.
  • In the past 5 years, Pharming's EPS (Weighted Average and Diluted) registered a high of -$11120.8 during Q1 2021, and its lowest value of -$1.9 million during Q4 2019.
  • Over the past 3 years, Pharming's median EPS (Weighted Average and Diluted) value was -$639230.5 (recorded in 2020), while the average stood at -$849941.7.
  • Over the last 5 years, Pharming's EPS (Weighted Average and Diluted) had its largest YoY gain of 6634.7% in 2020, and its largest YoY loss of 6634.7% in 2020.
  • Over the past 3 years, Pharming's EPS (Weighted Average and Diluted) (Quarter) stood at -$1.9 million in 2019, then skyrocketed by 66.35% to -$639230.5 in 2020, then soared by 98.26% to -$11120.8 in 2021.
  • Its EPS (Weighted Average and Diluted) was -$11120.8 in Q1 2021, compared to -$639230.5 in Q4 2020 and -$1.9 million in Q4 2019.